About Inspire Medical Systems, Inc. Common Stock (INSP)
Inspire Medical Systems is a medical device company focused on developing innovative solutions to treat obstructive sleep apnea. The company specializes in the design and manufacturing of implantable neurostimulation devices that work to improve airflow during sleep by stimulating the hypoglossal nerve, which helps keep the airway open. Their technology aims to provide an effective alternative for individuals who are unable to tolerate traditional continuous positive airway pressure (CPAP) therapy. Through its pioneering approach, Inspire Medical Systems is committed to enhancing the quality of life for patients with sleep-disordered breathing conditions. Read More
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Inspire Medical Systems, Inc. (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”). Inspire Medical is a medical technology company.
NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE:INSP) securities during the period of August 6, 2024 through August 4, 2025, inclusive (“the Class Period”).
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) (NYSE: INSP) and reminds investors of the January 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inspire Medical (INSP) To Contact Him Directly To Discuss Their Options
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Inspire Medical Systems, Inc. (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, inclusive (the “Class Period”), have until January 5, 2026 to seek appointment as lead plaintiff of the Inspire Medical class action lawsuit. Captioned City of Pontiac Reestablished General Employees’ Retirement System v. Inspire Medical Systems, Inc., No. 25-cv-04247 (D. Minn.), the Inspire Medical class action lawsuit charges Inspire Medical and certain of Inspire Medical’s top executives with violations of the Securities Exchange Act of 1934.
Today, Grant & Eisenhofer P.A. filed a class action lawsuit on behalf of City of Pontiac Reestablished General Employees’ Retirement System against Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) and three of the Company’s senior executives, including CEO Timothy Herbert, CFO Richard Buchholz, and Chief Strategy and Growth Officer Carlton Weatherby (collectively, the “Defendants”). The action alleges that Defendants defrauded investors by making materially false and/or misleading statements and by failing to disclose materially adverse facts concerning the launch of the Company’s new product, a sleep apnea device called “Inspire V.”
Shares of medical technology company Inspire Medical Systems (NYSE:INSP)
jumped 16.2% in the morning session after the company reported strong third-quarter results that significantly surpassed Wall Street's expectations for both revenue and profit.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Medical technology company Inspire Medical Systems (NYSE:INSP) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 10.5% year on year to $224.5 million. The company expects the full year’s revenue to be around $905 million, close to analysts’ estimates. Its GAAP profit of $0.34 per share was significantly above analysts’ consensus estimates.
Medical technology company Inspire Medical Systems (NYSE:INSP) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 10.5% year on year to $224.5 million. The company expects the full year’s revenue to be around $905 million, close to analysts’ estimates. Its GAAP profit of $0.34 per share was significantly above analysts’ consensus estimates.
Shares of medical technology company Inspire Medical Systems (NYSE:INSP)
fell 3.4% in the afternoon session after Jefferies downgraded the stock to Hold from Buy and sharply reduced its price target to $85 from $160. The downgrade followed the firm's U.S. sleep survey, which pointed to ongoing headwinds from the uptake of GLP-1 weight loss medications and market share gains by competitors. The analyst also noted "muted expectations" for volume growth related to the company's Inspire 5 product line. Other contributing factors included concerns about physician reimbursement and what was described as a recent history of "execution challenges" at the medical device company.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
What a brutal six months it’s been for Inspire Medical Systems. The stock has dropped 44.2% and now trades at $83, rattling many shareholders. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Discover how Inspire Medical's strong growth and breakout chart pattern create a compelling investment case using a combined fundamental and technical screen.
